Doesn't sound like it's failed yet, it just didn't meet something called the threshold of probability for success according to pre-determined criteria, or something like that. That statement most probably takes more into consideration far more than simply the rate of patient success.
But they haven't dropped the trial yet, and only will after a full data review in FQ 2020, so it's far from the shredder.
Besides, maybe the share price has effected trials and this study may be placed on the back burner for now.
But, what the hell do I know, I'm invested right along with you in a stock where the CEO seems determined to trash it.
News 
Market Data 
Discover 
